Long-term survival after high-dose-rate brachytherapy for locally advanced or recurrent colorectal adenocarcinoma Journal Article


Authors: Terezakis, S.; Morikawa, L.; Wu, A.; Zhang, Z.; Shi, W.; Weiser, M. R.; Paty, P. B.; Guillem, J.; Temple, L.; Nash, G. M.; Zelefsky, M. J.; Goodman, K. A.
Article Title: Long-term survival after high-dose-rate brachytherapy for locally advanced or recurrent colorectal adenocarcinoma
Abstract: Background: We evaluated outcomes of intraoperative radiotherapy delivered with focal high-dose-rate (HDR) brachytherapy [intraoperative radiotherapy (IORT)] in the management of locally recurrent (LR) and locally advanced (LA) primary T4 colorectal carcinoma (CRC). LR CRC or LA primary disease is a clinical challenge due to the difficulty in obtaining negative margins after radical surgery and the high risk of subsequent recurrence. Few data exist on long-term outcomes of patients treated with surgery and HDR-IORT for LR or LA primary CRC. Methods: Three hundred CRC patients underwent HDR-IORT to the pelvis with gross surgical resection during November 1992–December 2007. Median follow-up for surviving patients was 53 (range 5–216) months. Eighty-eight patients (29 %) were treated for LA primary and 212 (71 %) LR disease. HDR-IORT was delivered using an iridium-192 remote afterloader and a Harrison–Anderson–Mick applicator. Median IORT dose was 1,500 (range 1,000–2,000) cGy. Results: Five-year overall survival probability was 49 %. Positive margin status was associated with inferior overall survival and disease-free survival. Competing-risks analysis for time to local failure and distant metastases identified a 5-year cumulative incidence of local failure and distant metastases of 33 and 47 %, respectively. Five-year cumulative incidence of local failure was 22 % for the LA group and 38 % in the LR group. Five-year probability of disease-free survival was 48 and 31 % for LA and LR patients, respectively, and 5-year probability of overall survival was 56 and 45 % for LA and LR patients, respectively. Conclusions: HDR-IORT combined with resection results in encouraging local control rates with acceptable toxicity for patients with locally aggressive CRC. © 2015, Society of Surgical Oncology.
Keywords: cancer survival; controlled study; cancer surgery; treatment failure; major clinical study; overall survival; cancer recurrence; fluorouracil; advanced cancer; cancer combination chemotherapy; cancer risk; patient selection; disease free survival; radiation dose; outcome assessment; follow up; cancer incidence; pelvis; disease association; multiple cycle treatment; peripheral neuropathy; clinical assessment; local therapy; radiation injury; risk factor; distant metastasis; high risk patient; risk assessment; colorectal carcinoma; liver metastasis; lung metastasis; clinical evaluation; pelvis exenteration; ureter disease; brachytherapy; recurrent disease; oxaliplatin; wound complication; iridium 192; bladder disease; pelvis surgery; intraoperative radiotherapy; abscess; high dose rate; gastrointestinal obstruction; preoperative radiotherapy; gastrointestinal infection; digestive system fistula; long term survival; radiation applicator; human; male; female; article
Journal Title: Annals of Surgical Oncology
Volume: 22
Issue: 7
ISSN: 1068-9265
Publisher: Springer  
Date Published: 2015-07-01
Start Page: 2168
End Page: 2178
Language: English
DOI: 10.1245/s10434-014-4271-8
PROVIDER: scopus
PUBMED: 25631062
PMCID: PMC5316234
DOI/URL:
Notes: Export Date: 2 July 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Zhigang Zhang
    428 Zhang
  2. Michael J Zelefsky
    754 Zelefsky
  3. Weiji Shi
    121 Shi
  4. Philip B Paty
    499 Paty
  5. Karyn A Goodman
    257 Goodman
  6. Jose Guillem
    414 Guillem
  7. Martin R Weiser
    538 Weiser
  8. Abraham Jing-Ching Wu
    401 Wu
  9. Garrett Nash
    263 Nash
  10. Larissa Temple
    193 Temple